Granahan Investment Management Inc. MA boosted its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 8.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,582 shares of the company’s stock after buying an additional 2,655 shares during the period. Granahan Investment Management Inc. MA owned approximately 0.06% of Crispr Therapeutics worth $1,418,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of CRSP. Nikko Asset Management Americas Inc. boosted its stake in Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after purchasing an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC boosted its stake in Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Crispr Therapeutics during the 2nd quarter valued at about $5,165,000. 49.82% of the stock is owned by institutional investors and hedge funds.

NASDAQ:CRSP opened at $65.36 on Friday. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $58.93 and its 200 day moving average is $48.44. Crispr Therapeutics AG has a 12 month low of $22.22 and a 12 month high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities research analysts anticipate that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 in the last ninety days. 21.40% of the stock is currently owned by insiders.

CRSP has been the subject of a number of analyst reports. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Canaccord Genuity boosted their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, Chardan Capital restated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Buy” and a consensus price target of $69.54.

Crispr Therapeutics Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Initial Coin Offerings entail a high degree of risk

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link